Sarepta Therapeutics reported second-quarter 2025 revenue of $611.1 million, a 68% increase from the prior year, and swung to GAAP net income of $196.9 million from $6.5 million. Adjusted earnings reached $2.02 a share, comfortably ahead of the $1.16 analysts had expected. Net product revenue totalled $513.1 million, led by $282 million from the Duchenne muscular dystrophy gene therapy Elevidys, while a $63.5 million milestone from partner Roche following Japanese approval of the therapy also buoyed results. The quarter was cash-flow positive, adding $202.8 million to Sarepta’s cash, cash equivalents and investments. Management said a restructuring unveiled in July remains on course to deliver more than $100 million of operating savings this year and approximately $400 million annually from 2026, supporting repayment of 2027 convertible notes and further investment in the company’s siRNA pipeline. Operationally, the U.S. Food and Drug Administration on 28 July cleared the resumption of Elevidys shipments for ambulatory patients after a brief voluntary pause tied to liver-safety concerns. Discussions continue with the agency on label updates and a risk-mitigation plan before shipments restart for non-ambulatory patients. Sarepta expects additional clinical readouts across its siRNA programmes for facioscapulohumeral muscular dystrophy, myotonic dystrophy and spinocerebellar ataxia later this year.